A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis.

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 Results comparing the efficacy of subcutaneous (SC) peginterferon beta-1a and oral teriflunomide in patients from four randomised trials (ADVANCE, ATTAIN, TEMSO and TOWER), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results comparing the effectiveness of subcutaneous peginterferon beta-1a and intramuscular interferon (IFN) beta-1a in patients from two randomised trials (ADVANCE and DECIDE), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of pooled analysis comparing SC IFN beta-1a with SC peginterferon beta-1a using patient data from ADVANCE, OPERA I, OPERA II, CARE-MS I, CARE-MS II trials, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top